Image_3_Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner.tif by Kai Li (205203)

Image_8_Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner.tif by Kai Li (205203)

Image_9_Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner.tif by Kai Li (205203)

Image_4_Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner.tif by Kai Li (205203)

Image_7_Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner.tif by Kai Li (205203)

Image_5_Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner.tif by Kai Li (205203)

Image_6_Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner.tif by Kai Li (205203)

Image_10_Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner.tif by Kai Li (205203)

Supplementary Material for: Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study by figshare admin karger (2628495)

“…Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), a prevalent condition, can progress to liver cirrhosis and hepatocellular carcinoma. …”

Vinculin concentration can influence maturation fraction. by Kailas Shankar Honasoge (17108745)

Differences in abundance of non-lipid molecules in liver of <i>Fmo5</i>^<i>-/-</i> and WT mice. by Ian R. Phillips (5074121)

“…Non-lipid data points were abstracted after analysis of all metabolites in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0286692#pone.0286692.s001" target="_blank">S1 Table</a> combined. …”

Efficacy of topical brinzolamide in children with retinal dystrophies by Brittni A. Scruggs (511698)

“…Four of the six treated patients exhibited a mild decrease in central macular thickness in both eyes during the study with all six treated patients having significantly improved vision at the first endpoint, 33.2 ± 8.2 months after treatment initiation. …”

H3N2 hexamaps for HAI titers. by Andrew F. Brouwer (12119842)

Data Sheet 2_Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus.docx by Haoyi Yang (8215116)

“…</p>Study design<p>In the phase Ib study, a total of 50 participants with T2DM were enrolled and randomly assigned to the 0.5 mg BID, 1 mg BID, 2 mg BID, 1 mg QD, and 2 mg QD dose groups, with a 4:1 random allocation within each group to receive either the SY-009 capsule or placebo. …”

Data Sheet 1_Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus.docx by Haoyi Yang (8215116)

“…</p>Study design<p>In the phase Ib study, a total of 50 participants with T2DM were enrolled and randomly assigned to the 0.5 mg BID, 1 mg BID, 2 mg BID, 1 mg QD, and 2 mg QD dose groups, with a 4:1 random allocation within each group to receive either the SY-009 capsule or placebo. …”

The application of rumen simulation technique (RUSITEC) for studying dynamics of the bacterial community and metabolome in rumen fluid and the effects of a challenge with <i>Clostr... by Stefanie U. Wetzels (3203955)

“…Along the time-line, there was no statistically significant change of the overall bacterial community, however, some phylotypes were enriched at certain time points. A decrease in <i>Fibrobacter</i> and <i>Elusimicrobia</i> over time was followed by an increase in <i>Firmicutes</i> and <i>Actinobacteria</i>. …”

H1N1 hexamaps for HAI titers. by Andrew F. Brouwer (12119842)

Differences in abundance of lipid molecules in liver of <i>Fmo5</i>^<i>-/-</i> and WT mice. by Ian R. Phillips (5074121)

“…Lipid data points were abstracted after analysis of all metabolites in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0286692#pone.0286692.s001" target="_blank">S1 Table</a> combined. …”

S1 Dataset - by Pamela Bakkabulindi (12914980)

“…At the endline, immunization coverage for the Oral Polio Vaccine third dose; Rotavirus vaccine second dose; Pneumococcal Conjugate Vaccine third dose increased in both the intervention and control health facilities. There was a decrease in coverage for the Measles-Rubella vaccine decreased in the intervention health facilities and a decrease in Bacillus Calmette–Guérin vaccine coverage in the control facilities. …”

Data_Sheet_1_A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes.DOC... by Azam Doustmohammadian (8488608)

“…<p>The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg sitagliptin (n = 60) or the placebo (n = 60) for 56 weeks and lifestyle modification in both groups. …”